Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer: One More ADC or a New Opportunity? Mosele MF, Andre F. JAMA 2026 Oct 23. doi: 10.1001/jama.2026.22295.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mosele MF, Andre F. Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer: One More ADC or a New Opportunity? JAMA 2026 Oct 23. doi: 10.1001/jama.2026.22295.
PMID: 42924935